Several times a year, a Confident Investor must reevaluate the companies in the portfolio. Keeping your money in a stock that no longer qualifies as a “Good” company can end up hurting your investment performance a great deal. Also, there are a lot of Good Companies so losing the worst of the best is not going to impact the ability to have a balanced portfolio. Over the coming days, this site will evaluate each stock on the Watch List.
|Company name||Alexion Pharmaceuticals, Inc.|
|Live stock price||[stckqut]ALXN[/stckqut]|
|P/E compared to competitors||Fair|
|Confident Investor Rating||Good|
|Target stock price (TWCA growth scenario)||$145.74|
|Target stock price (averages with growth)||$211.41|
|Target stock price (averages with no growth)||$116.75|
|Target stock price (manual assumptions)||$112.48|
The following company description is from Google Finance: http://www.google.com/finance?q=alxn
Alexion Pharmaceuticals, Inc. (Alexion) is a biopharmaceutical company, which is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. for the production of Soliris.
Confident Investor comments: At this price and at this time, I think that a Confident Investor can confidently invest in this stock.